SGLT-2 inhibition has been shown to be effective in people with albuminuric chronic kidney disease across broad population, including people with and without type 2 diabetes, and down to an eGFR of 20 mL/min/1.73m2 [1–4]. Here, SLC5A2 is linked to chronic kidney disease.